AbbVie (ABBV) Tops Q1 EPS by 9c; Boosts FY15 EPS Outlook

AbbVie (NYSE: ABBV) reported Q1 EPS of $0.94, $0.09 better than the analyst estimate of $0.85. Revenue for the quarter came in at $5.04 billion versus the consensus estimate of $4.98 billion.

AbbVie sees FY2015 EPS of $4.10-$4.30, versus the consensus of $4.19.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• AeroVironment restates quarterly financials, citing $89M goodwill error
• This digital health stock is ready to re-rate higher: Goldman
• Apogee Therapeutics, BitFuFu rise premarket; AbbVie gains after deal